Sodium selenate, which increases PP2A activity, reduced cognitive impairment in a PP2A-dependent manner in AD models based on dysregulated tau phosphorylation (Corcoran et al., 2010; van Eersel et al., 2010). The gene discussed is MAPT; the disease is Alzheimer disease.